Summarized by Masters of Longevity from Longevity Technology.
London startup rebrands and secures $60 million while unveiling a compact tau degrader approach.

Key Takeaways
- Bifunctional degraders are often too large for the blood–brain barrier.
- Oyster has raised $60 million to develop tau degrader delivery.
- Smaller degraders and transport tactics may enable brain targeting.



